|
|
|
|
| LEADER |
01611nam a2200265 u 4500 |
| 001 |
EB002002159 |
| 003 |
EBX01000000000000001165060 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 245 |
0 |
0 |
|a Drugs for chronic hepatitis C infection
|h Elektronische Ressource
|b recommendations report
|c CADTH.
|
| 250 |
|
|
|a Version 1.0
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c November 2015, 2015
|
| 300 |
|
|
|a 1 PDF file (iii, 28 pages)
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Canada
|
| 653 |
|
|
|a Antiviral Agents / therapeutic use
|
| 653 |
|
|
|a Hepatitis C, Chronic / drug therapy
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH therapeutic review
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK355804
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a Evidence-informed recommendations were developed by the CADTH Canadian Drug Expert Committee (CDEC) to address the following policy questions: 1. How should interferon-free direct-acting antiviral agent (DAA) regimens be listed for reimbursement for chronic hepatitis C (CHC) infection (genotypes 1 to 6)?2. Should reimbursement of regimens for CHC infection be guided by fibrosis staging and limited to fibrosis stages e F2?3. Should re-treatment with a DAA regimen be reimbursed for patients with CHC infection who fail to achieve sustained virologic response (SVR) on another DAA regimen?
|